[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"recurrent-miscarriage\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:recurrent-miscarriage":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,49,78,105,131,155],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":31,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100489055","immune-profile-analysis-and-biomarker-identification-in-women-with-repeated-implantation-failure-or-unexplained-recurrent-spontaneous-miscarriage-100489055",false,"NCT05648136","Immune Profile Analysis and Biomarker Identification in Women With Repeated Implantation Failure or Unexplained Recurrent Spontaneous Miscarriage","ERIM","Inclusion Criteria:\n\n* For patients :\n* Women aged 18 to 39 years\n* women with a history of RIF or unexplained RM\n* women with a negative diagnostic work-up (including pelvic ultrasound and hysteroscopy, parental karyotype, thyroid function test, and anti-thyroid and anti-phospholipid antibodies)\n* women with a basal FSH level \\\u003C10IU\u002Fl and AMH level \\>1.5ng\u002Fml\n* women with a regular menstrual cycle of 30+\u002F-5 days\n* women receiving a new cycle of in vitro fertilization (IVF) +\u002F- intracytoplasmic sperm injection (ICSI) for patients in the RIF group or a first cycle of IVF +\u002F-ICSI for patients in the RM group\n* women received written and oral information and signed an informed consent\n\nFor control groups:\n\n* Controls recruited in the Obstetrics and Gynecology Department with at least one live birth after a spontaneous pregnancy (with a time to conception of less than 12 months for each pregnancy) Voluntary oocyte donors recruited within the CECOS de Picardie (having presented at least one live birth with a delay necessary to conceive of less than 12 months)\n* Controls recruited in the Reproductive Medicine and Biology Department having presented at least one live birth (spontaneous with a delay to conceive of less than 12 months for each pregnancy or after one or two MPA procedures) and benefiting from an IVF+\u002F-ICSI procedure for secondary infertility\n* Controls recruited in the department of Medicine and Reproductive Biology with a normal infertility assessment and benefiting from an IVF procedure with ICSI on male indication.\n\nExclusion Criteria:\n\n* Ongoing pelvic and\u002For systemic infection\n* Chronic infectious endometritis\n* Active neoplasia\n* Autoimmune and autoinflammatory disease\n* Celiac disease\n* Thrombophilia (including positive anti-phospholipid antibodies)\n* Endocrine pathology (including dysthyroidism and diabetes)\n* Endometriosis\n* Polycystic ovary syndrome and ovulatory disorders\n* Premature ovarian failure\n* IVF by oocyte donation\n* Tubal obstructions or lesions, uterine and cervical anomalies\n* Partners with extreme oligoastheno-spermia and\u002For sperm DNA fragmentation \\>30\n* Sperm donations\n* Patients unable to give informed consent",true,"FEMALE","18 Years","39 Years",{"count":21,"type":22},150,"ESTIMATED","INTERVENTIONAL",[25],"NA","Implantation is a determining step in human reproduction which requires the transition from a pro-inflammatory state to an anti-inflammatory state allowing the implantation of a competent embryo within a receptive endometrium, and then the maternal immunotolerance towards the alloantigenic fetus. Repeat implantation failures (RIFs), that refers to the fail to achieve a clinical pregnancy after the transfer of at least 3-4 good quality embryos or two blastocysts, and unexplained recurrent spontaneous miscarriage (RM) (≥2-3) could be related in some patients to immune imbalances characterized by an excessive and prolonged inflammatory response and\u002For a defect of anti-inflammatory regulation. In this context, several therapies have been evaluated in patients with RIFs or RMs in order to restore the immune balance, with heterogeneous results. No serum biomarker assay has been routinely approved to identify patients with immune imbalances that may explain repeated pregnancy failures and to predict the success of the subsequent IVF\u002FICSI cycle. The immunological analysis on peripheral blood will be based on the determination of the proportions of immune subpopulations (e.g. CD4+ et CD8+, TH1, TH2, TH17, Treg, ILC 1, ILC2, and ILC3) on the one hand and the circulating level of plasma cytokines on the other hand.",[28,29,30],"Repeated Embryo Implantation Failure","Recurrent Miscarriage","Immune System",[32,33,34,35],"repeated embryo implantation failure","recurrent spontaneous miscarriage","immunological analysis","immune system","RECRUITING","2026-06-10",{"date":39,"type":40},"2026-06-11","ACTUAL",{"date":42,"type":40},"2024-08-26",{"date":44,"type":22},"2026-08",{"name":46,"class":47},"Centre Hospitalier Universitaire, Amiens","OTHER",1,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":4,"eligibilityCriteria":55,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":56,"enrollmentInfo":57,"targetDuration":4,"studyType":59,"phases":4,"briefSummary":60,"conditions":61,"keywords":64,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":48},"100579597","immune-cell-populations-in-the-endometrium-100579597","NCT06826365","Immune Cell Populations in the Endometrium","Analysis of Immune Cell Populations in the Endometrium and Peripheral Blood in Women With Reduced and Normal Fertility","Inclusion Criteria:\n\n* age 18-45 years\n* idiopathic infertility\n* at least 2 miscarriages\n* other benign gynecological conditions subjected to endometrial sampling\n\nExclusion Criteria:\n\n* miscarriage within last 3 months\n* abdominal\u002Futerine surgery within last 3 months\n* viral\u002Fbacterial infection within last 3 months\n* antibiotic therapy within last 3 months","45 Years",{"count":58,"type":22},50,"OBSERVATIONAL","Specialized immunological studies in the diagnostics of idiopathic infertility and recurrent miscarriages have limited applicability, as the role of the immune system in these conditions is not thoroughly understood. In ovulatory cycles, changes occur in the populations of uterine lymphocytes, which may influence the receptivity of the endometrium and the implantation of the embryo. Particularly notable are the changes in natural killer (NK) cells, which reach their peak during the luteal phase and regulate the invasion of the trophoblast. The dominant NK cells exhibit a CD56bright phenotype and differ in cytokine profiles from peripheral blood cells. Cyclical changes also affect macrophages and T lymphocytes; however, it is unclear whether their proportions differ in women with reduced fertility. There is a need to investigate how the composition of lymphocytes in blood influences the populations in the endometrium. The aim of this study is to analyze the correlation between peripheral and endometrial lymphocytes in women with idiopathic infertility and recurrent miscarriages, compared to fertile women.",[62,29,63],"Infertility, Female","Gynecologic Disease",[65,66,67,68],"Idiopathic infertility","Endometrial immunology","Endometrial aspiration biopsy","Recurrent miscarriage","2026-03-17",{"date":71,"type":40},"2026-03-19",{"date":73,"type":40},"2025-07-01",{"date":75,"type":22},"2026-06-30",{"name":77,"class":47},"Jagiellonian University",{"id":79,"slug":80,"hasResults":11,"nctId":81,"briefTitle":82,"officialTitle":83,"acronym":4,"eligibilityCriteria":84,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":85,"enrollmentInfo":86,"targetDuration":4,"studyType":59,"phases":4,"briefSummary":88,"conditions":89,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":97,"startDateStruct":99,"completionDateStruct":101,"leadSponsor":103,"locationsCount":48},"100452287","association-between-plasma-level-of-mannose-binding-lectin-and-human-reproduction-100452287","NCT05169541","Association Between Plasma Level of Mannose Binding Lectin and Human Reproduction","Is Plasma Level of Mannose Binding Lectin Associated With Reproductive Failure?","Inclusion Criteria:\n\nfulfil one of the following:\n\n* 3 consecutive pregnancy losses after spontaneous conception\n* 3 consecutive pregnancy losses after assisted reproductive technology treatment (ART) including IVF, ICSI and FET\n* 3 failed embryo transfers characterized by no achieved pregnancy (after 3 cycles with minimum 1 embryo transfer of a good-quality embryo in each cycle.)\n\nExclusion Criteria:\n\n* Age \\\u003C18 or \\>45 years\n* AMH \\\u003C4.0 pmol\u002Fl unless donor egg in previous cycles\n* Significant uterine malformation\n* Known endometrial pathologies including intrauterine endometriosis, adenomyosis, hyperplasia or polyps\n* Known chromosomal abnormalities\n* Pregnancy \\>9 weeks of gestation at the time collecting the blood sample","41 Years",{"count":87,"type":22},500,"A low plasma level of mannose binding lectin (p-MBL) is associated with unexplained recurrent pregnancy loss (RPL), but it is not investigated if it is associated with unexplained reproductive failure in general, including recurrent implantation failure (RIF) after assisted reproductive technology (ART) (including IVF, ICSI and FET), recurrent pregnancy loss (RPL) after spontaneous conception, and RPL after ART.",[90,91,92,93,94,29,95],"Mannose-Binding Lectin Deficiency","Recurrent Pregnancy Loss","Recurrent Implantation Failure","Infertility","Habitual Abortion","Recurrent Spontaneous Abortion","2025-11-20",{"date":98,"type":40},"2025-11-24",{"date":100,"type":40},"2016-01-01",{"date":102,"type":22},"2026-11-30",{"name":104,"class":47},"Aalborg University Hospital",{"id":106,"slug":107,"hasResults":11,"nctId":108,"briefTitle":109,"officialTitle":110,"acronym":4,"eligibilityCriteria":111,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":112,"enrollmentInfo":113,"targetDuration":4,"studyType":23,"phases":115,"briefSummary":117,"conditions":118,"keywords":119,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":122,"lastUpdatePostDateStruct":123,"startDateStruct":125,"completionDateStruct":127,"leadSponsor":129,"locationsCount":48},"100355051","phase-3-effect-of-prednisolone-treatment-on-uterine-natural-killer-cells-100355051","NCT03902912","Effect of Prednisolone Treatment on Uterine Natural Killer Cells","Effect of Prednisolone Treatment on Uterine Natural Killer Cells and Endometrial Angiogenesis in Recurrent Miscarriage Around the Time of Embryo Implantation","Inclusion Criteria:\n\n1. Women with a history of 3 or more consecutive miscarriages\n2. Women younger than 40 years old\n\nExclusion Criteria:\n\n1. Allergy to prednisolone\n2. Women who have any uterine anomaly\n3. Antiphospholipid syndrome\n4. Hydrosalpinx\n5. Thrombophilia\n6. Abnormal thyroid function tests\n7. women with diabetes,","40 Years",{"count":114,"type":22},84,[116],"PHASE3","This study aims to investigate the role of uNK cells and the association with prednisolone.",[29],[120,121],"recurrent miscarriage","prednisolone treatment","2025-03-19",{"date":124,"type":40},"2025-03-21",{"date":126,"type":40},"2019-07-30",{"date":128,"type":22},"2028-04-30",{"name":130,"class":47},"Chinese University of Hong Kong",{"id":132,"slug":133,"hasResults":11,"nctId":134,"briefTitle":135,"officialTitle":136,"acronym":4,"eligibilityCriteria":137,"healthyVolunteers":11,"sex":17,"minAge":138,"maxAge":56,"enrollmentInfo":139,"targetDuration":4,"studyType":59,"phases":4,"briefSummary":141,"conditions":142,"keywords":143,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":147,"lastUpdatePostDateStruct":148,"startDateStruct":150,"completionDateStruct":152,"leadSponsor":154,"locationsCount":48},"100528616","chronic-endometritis-and-benefits-of-antibiotics-in-women-with-recurrent-miscarriage-100528616","NCT06163092","Chronic Endometritis and Benefits of Antibiotics in Women With Recurrent Miscarriage","The Prevalence of Chronic Endometritis and Therapeutic Benefits of Antibiotics in Women With Unexplained Recurrent Miscarriage","Inclusion Criteria:\n\n* Women with a history of 2 or more consecutive miscarriages before 24 weeks of gestation\n* Women aged 20-45 years old\n\nExclusion Criteria:\n\n* Uncorrected uterine anomalies, such as the septate or bicornuate uterus, fibroids (submucous\u002Fintramural)\n* Untreated hydrosalpinx\n* Antiphospholipid syndrome\n* Known clinical autoimmune disease\n* Undergoing immunotherapy\n* Abnormal thyroid function\n* Abnormal karyotyping of couples\n* Known immunodeficiency pathologies such as diabetes or HIV\n* Currently taking other antibiotics or other trial medications or TCM;\n* Currently or previously involved in other clinical trials with medication intake;\n* Those with active pelvic inflammatory disease or suspicion of infection etc.","20 Years",{"count":140,"type":22},175,"The aim of the study is to estimate the incidence of CE, evaluate the endometrial microorganism of CE, and investigate the therapeutic benefits of antibiotics for women with unexplained recurrent miscarriage and CE.",[29],[144,145,146],"chronic endometritis","antibiotics","unexplained recurrent miscarriage women","2025-03-18",{"date":149,"type":40},"2025-03-20",{"date":151,"type":40},"2024-04-01",{"date":153,"type":22},"2027-01-31",{"name":130,"class":47},{"id":156,"slug":157,"hasResults":11,"nctId":158,"briefTitle":159,"officialTitle":160,"acronym":161,"eligibilityCriteria":162,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":112,"enrollmentInfo":163,"targetDuration":4,"studyType":23,"phases":165,"briefSummary":167,"conditions":168,"keywords":171,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":174,"lastUpdatePostDateStruct":175,"startDateStruct":177,"completionDateStruct":179,"leadSponsor":181,"locationsCount":48},"100495002","phase-4-prednisolone-administration-in-patients-with-unexplained-recurrent-miscarriages-100495002","NCT05725512","Prednisolone Administration in Patients With Unexplained REcurrent MIscarriages","Prednisolone Administration in Patients With Unexplained REcurrent MIscarriages, PREMI Trial","PREMI","Inclusion Criteria:\n\nIn order to be eligible to participate in this study, a subject must meet all of the following criteria:\n\n* Unexplained recurrent pregnancy loss: defined as the loss of ≥2 pregnancies, without any known cause for RM (parental chromosomal abnormalities, uterine anomalies, acquired or hereditary thrombophilia, endocrine diseases (such as hypothyroidism or diabetes)).\n* The miscarriages include:\n\n  * all consecutive or non-consecutive pregnancy losses before the 24th week of gestation verified by ultrasonography or uterine curettage and histology\n  * non-visualized pregnancies (including biochemical pregnancy losses and\u002For resolved and treated pregnancies of unknown location), verified by positive urine or serum hCG Ectopic and molar pregnancies are not included\n* Age 18 - 39 years at randomization (likelihood of miscarriages due to chromosomal aberrations is higher when age \\> 39 years. Such miscarriages are unlikely to be pre-vented by prednisolone therapy)\n* Conception confirmed by urinary pregnancy test, with estimated gestational age ≤ 7weeks\n* Willing and able to give informed consent in English or Dutch (IC)\n\nExclusion Criteria:\n\nA potential subject who meets any of the following criteria will be excluded from participation in this study:\n\n* Any of the following diagnosis for the recurrent miscarriages\n\n  * Antiphospholipid syndrome (lupus anticoagulant and\u002F or anticardiolipin anti-bodies and\u002For beta-2 glycoprotein \\[IgG or IgM)\n  * Congenital uterine abnormalities (as assessed by 2D or 3d ultrasound, hys-terosonography, hysterosalpingogram or hysteroscopy)\n  * Abnormal parental karyotype\n* Instable or exacerbation of auto-immune diseases such as diabetes, thyroid disease, inflammatory bowel diseases or SLE\n* Inability to conceive within 1 year of recruitment\n* Current treatment with systemic prednisolone or other immune suppressive medication (for any indication)\n* Previous enrolment in the PREMI trial\n* Enrolment in any other trial that studies the effectiveness of an intervention on RM\n* Contraindications to prednisolone use:\n\n  * Known allergy for prednisolone\n  * Acute bacterial infection or parasite infection\n  * Active COVID infection\n  * Systemic sclerosis\n  * Ulcus ventriculi or ulcus duodeni in medical history\n  * Obesity with BMI \\>40\n* Some drugs are known to interact with Prednisolone, and thus women on the following drugs are not eligible to take part in the PREMI trial:\n\n  * Enzyme inducers, such as carbamazepine, fenobarbital, fenytoïne and ri-fampicine\n  * CYP3A inhibitors, such as Cobicistat or Ritonavir\n  * Cyclosporine\n  * Digoxin\n  * Vaccination (with inactivated virus or bacteria) during prednisolone use is possibly less effective",{"count":164,"type":22},490,[166],"PHASE4","Recurrent miscarriages (RM) affects 3% of all fertile couples, but remains unexplained in most cases, limiting therapeutic options. Possibly the maternal immune system plays a role in recurrent miscarriage. Prednisolone suppresses the immune system and might enable development of normal pregnancy.\n\nIn this randomized controlled clinical trial the investigators will study the effect of prednisolone on the live birth rate in patients with RM. Secondary, the tolerability and safety for mother and child and the cost-effectiveness is investigated.\n\nIn the study one group of pregnant women with RM and gestational age \\\u003C7 weeks will receive prednisolone, the other group will receive a placebo. Total use of the medicine during this study is 8 weeks, further care during the study is routinely antenatal care. Subjects will be asked to fill in 4 short questionnaires and will have contact with a research nurse at different time points to gain information on the course of the pregnancy and possible side effects.\n\nResults of the study will be implemented in (inter) national guidelines, to effect everyday practice.",[29,91,94,169,170],"Miscarriage","Fertility Disorders",[172,68,173],"Recurrent pregnancy loss","prednisolone","2024-05-23",{"date":176,"type":40},"2024-05-24",{"date":178,"type":40},"2024-01-29",{"date":180,"type":22},"2027-07-29",{"name":182,"class":47},"Leiden University Medical Center"]